Form 4: Director Andrew Levin Receives Vor Biopharma Stock Options

Director Andrew David Levin was granted 57,162 stock options in Vor Biopharma Inc. as part of his service arrangement.

Summary

• Director Andrew David Levin received a grant of 57,162 stock options on June 11, 2026.
• The options have an exercise price of $14.09 per share.
• The options expire on June 10, 2036.
• Vesting occurs in 36 equal monthly installments starting July 11, 2026, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is subject to the continued service of the director, creating a dependency on personnel retention.

Future Outlook

The options vest monthly over a three-year period, indicating a long-term commitment to the company's service.

Management Comments

• The reporting person disclaims beneficial ownership of the option and underlying common stock, as they are held for the benefit of RA Capital Healthcare Fund, L.P.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize board members and align their interests with the long-term success of clinical-stage companies.

Comparison to Industry Standards

• The 36-month vesting schedule is consistent with standard corporate governance practices for director equity compensation in the life sciences industry.

Related Party Transactions

• The reporting person holds the options for the benefit of RA Capital Healthcare Fund, L.P. and is obligated to turn over net proceeds to the Adviser to offset advisory fees.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Commencement of monthly vesting on July 11, 2026.

Key Dates

Keywords

Vor Biopharma, VOR, Form 4, Insider Trading, Stock Options, Director Compensation